Medical Device Industry
Filter News
Found 11,830 articles
-
The partners will combine Miromatrix’s single-use bioengineered liver with Baxter’s PrisMax system, which is designed to provide individualized therapies to patients.
-
Sequana Medical announces grant of additional DSR® patent in United States
2/1/2023
Ghent, Belgium – 1 February 2023– Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces the grant of an additional US patent for its DSR program.
-
Occlutech Announces Change to the Executive Management Team
2/1/2023
Occlutech Holding AG Occlutech Holding AG, one of the world's leading providers of minimally invasive structural heart disease devices, appoints Dr. Morwan Choli as the new Vice President of Regulatory Affairs & Quality.
-
Nevro to Present at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference
2/1/2023
Nevro Corp. today announced that D. Keith Grossman , Nevro's Chairman, CEO and President, and Rod MacLeod , Nevro's CFO, will participate in a fireside chat at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference on Wednesday, March 1, 2023 at 8:45 am Eastern Time at Citigroup's Corporate Headquarters in New York, NY.
-
MicroTransponder Secures CMS Transitional Pass-Through Status & New Technology Add-On Payment for Its Breakthrough Stroke Rehabilitation System, Vivistim
1/31/2023
MicroTransponder®, Inc. announces that the Centers for Medicare and Medicaid Services awarded the Vivistim® Paired VNS™ System transitional pass-through status, expanding access to Medicare beneficiaries who are ischemic stroke survivors interested in using the breakthrough technology to help improve their hand and arm mobility.
-
Publication Analyzes Clinical Efficacy of Deep TMS™ in Treating Different Brain Regions Associated with Major Depressive Disorder
1/31/2023
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced the publication of a comparative study of BrainsWay’s Deep Transcranial Stimulation H1 Coil, which targets the lateral prefrontal cortex, and the Company’s H7 Coil, which targets the medial prefrontal cortex.
-
VentureMed Group Raises Bridge Financing and Embarks on 2023 Objectives
1/31/2023
VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease announced that the company has raised bridge financing to support its 2023 objectives.
-
Sharps Technology Ships First Containers of Safety Syringes to Nephron Pharmaceuticals for Commercialization
1/31/2023
Sharps Technology, Inc. announces the first shipments of product from its wholly owned manufacturing facility in Hungary to Nephron Pharmaceuticals to advance the Company's first commercial operations.
-
Edwards Lifesciences Reports Fourth Quarter 2022 Results
1/31/2023
Edwards Lifesciences reported financial results for the quarter ended December 31, 2022.
-
Occlutech Continues its Progress in US FDA Study OCCLUFLEX – Enrolls First Patient in Europe
1/31/2023
Occlutech Holding AG, one of the world's leading providers of minimally invasive structural heart disease devices, continues its progress in the US market.
-
Inari Medical to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
1/31/2023
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will participate virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 14, 2023.
-
Vision Research Supplies Embedded Phantom High-Speed Camera for Use With FDA-Cleared Sepsis Test
1/30/2023
Vision Research, a leading manufacturer of digital high-speed imaging systems, has for the first time supplied an embedded Phantom high-speed camera for use within a medical device with U.S. Food and Drug Administration (FDA) 501(k) clearance.
-
ScreenPro Announces Grant of Stock Options
1/30/2023
ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) ("ScreenPro" or the "Company") is pleased to announce that the Company has granted stock options ("Options") to employees, officers and directors of the Company.
-
Extraordinary General Meeting of February 15, 2023: Notice of publication of the preparatory documents
1/27/2023
Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, informs its shareholders that an Extraordinary General Meeting of the Company will be held on Wednesday February 15, 2023, at 2.00 pm CET at the headquarter of Pixium Vision, 74 rue du faubourg Saint Antoine in Paris.
-
Sight Sciences Announces 1,000th TearCare® Customer Installation
1/26/2023
Sight Sciences, Inc. an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, announced the 1,000th installation of its TearCare® System.
-
Cardiac Dimensions Appoints Angie Swenson as Vice President, Clinical Operations
1/26/2023
Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, announced the appointment of Angie Swenson as Vice President of Clinical Operations.
-
Alleviant Medical Closes $75M in Financing; Receives FDA IDE Approval for Pivotal Clinical Trial
1/26/2023
Alleviant Medical, Inc. today announced the closing of a $75 million equity financing co-led by S3 Ventures and RiverVest Venture Partners.
-
Francis Medical Appoints Andrew Cleeland to Board of Directors
1/26/2023
Francis Medical, Inc., a privately-held medical device company developing an innovative and proprietary water vapor ablation therapy for the treatment of prostate, kidney, and bladder cancer, announced the appointment of Andrew Cleeland to the Francis Medical board of directors.
-
Paragon 28, Inc. Announces Pricing of Public Offering - Jan 26, 2023
1/26/2023
Paragon 28, Inc. announced the pricing of the previously announced underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $17.00 per share, before underwriting discounts and commissions.
-
Covalon Announces Fourth Quarter and Year End Results for Fiscal 2022 and Highlights Company Transformation Changes
1/26/2023
Covalon Technologies Ltd., an advanced medical technologies company, announced its fiscal 2022 fourth quarter and year end results for the period ended September 30, 2022.